Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
-- Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial of Reloxaliase in Enteric Hyperoxaluria (EH), with Statistically Significant Reduction in Urinary Oxalate (UOx) Compared to Placebo --
-- Reported Positive Data from Study 206 of Reloxaliase, Demonstrating Substantial Plasma Oxalate (POx) and UOx Reductions in Patients with EH and Advanced Chronic Kidney Disease (CKD) --
-- Plan to Pursue Accelerated Approval Based on URIROX-1 Data and Results of 24-Week Data from URIROX- 2--
-- Exploring Registrational Path for Reloxaliase in High-Risk EH Patients with CKD --
“We are excited about the presentation of positive topline results from URIROX-1 and Study 206 in EH patients that we presented at the
Recent Business Highlights and Upcoming Milestones:
Reloxaliase: Reloxaliase is a first-in-class, non-absorbed, orally administered enzyme for the treatment of severe hyperoxaluria. Allena is currently evaluating reloxaliase for patients with EH in the pivotal Phase 3 URIROX program, and for patients with EH and advanced CKD and elevated POx in the Phase 2 Study 206.
- URIROX-1 achieved its primary endpoint, with a mean reduction of 22.6% in average 24-hour UOx excretion measured during Weeks 1-4 in patients on reloxaliase, compared to 9.7% in patients on placebo (least square (LS) mean treatment difference of -14.3%,. p=0.004).
- The study approached statistical significance on the lead secondary endpoint, with 48.3% of patients on reloxaliase achieving a ≥20% reduction from baseline in 24-hour UOx excretion, compared to 31.6% of patients on placebo (p=0.06).
- In a pre-specified analysis of bariatric surgery patients (68% of the total study population), patients treated with reloxaliase achieved a mean reduction of 21.2% in average 24-hour UOx excretion, compared to 6.0% for patients treated with placebo (LS mean difference of -16.2%, p=0.01). In the stratified analysis of the key secondary endpoint, 50.0% of patients on reloxaliase achieved a ≥20% reduction from baseline in 24-hour UOx excretion, compared to 28.9% of patients on placebo (p=0.036).
- Consistent with prior clinical experience, reloxaliase was well-tolerated.
Allena continues to evaluate the full data from URIROX-1 and will assess the implications for URIROX-2, its second, larger pivotal Phase 3 trial, including the adaptive design elements of URIROX-2. URIROX-2 is ongoing, with topline data expected in the second half of 2021. Allena plans to file a Biologics License Application (BLA) with the
Also at ASN, Allena presented additional, positive data from Study 206. Study 206 has enrolled patients with EH and advanced CKD, which can lead to systemic oxalosis, a potentially life-threatening condition. This includes end-stage renal disease patients who are on dialysis and patients who have undergone kidney transplantation.
- Two patients with CKD Stage 3 demonstrated a substantial reduction in 24-hour UOx excretion (mean reductions of 29% and 42%, respectively) and in POx levels (mean reductions of 42% and 16%, respectively) over Weeks 4-12.
- Six patients with CKD Stage 5, including five patients on dialysis, demonstrated substantial reductions in POx levels over Weeks 4-12 (reductions ranged from 19% to 68%).
- Consistent with prior clinical experience, reloxaliase was generally well-tolerated out to 12 weeks of treatment.
Based on these results, Allena plans to meet with regulatory agencies in the first quarter of 2020 to discuss the registrational path for reloxaliase in high-risk EH patients with CKD.
ALLN-346: ALLN-346 is a first-in-class, orally administered, novel urate degrading enzyme that has been designed for activity and stability in the gastrointestinal tract. Allena is completing its preclinical development of ALLN-346 for the treatment of hyperuricemia in patients with gout in the setting of advanced CKD and also scaling its manufacturing processes to support clinical studies. Allena expects to file an Investigational New Drug (IND) application with the U.S.
Third Quarter 2019 Financial Results:
- Cash Position: As of September 30, 2019, cash and cash equivalents were $39.4 million, as compared to $61.6 million as of December 31, 2018. This decrease was primarily due to cash used in operating activities, partially offset by aggregate gross proceeds of approximately
$10 millionfrom the Company’s registered direct offering of common stock, which closed in June 2019.
- R&D Expenses: R&D expenses were $10.8 million for the third quarter of 2019, as compared to $7.3 million for the third quarter of 2018. The increase was primarily due to costs incurred for the URIROX-2 trial, which was initiated during the fourth quarter of 2018, and an increase of formulation and development costs incurred advancing ALLN-346.
- G&A Expenses: G&A expenses were $2.5 million for the third quarter of 2019, as compared to $2.4 million for the third quarter of 2018. The increase was primarily due to an increase in employee compensation and benefit costs.
- Net Loss: Net loss was $13.3 million for the third quarter of 2019, or a net loss per basic and diluted share of $0.57, as compared to a net loss of $9.5 million for the third quarter of 2018, or a net loss per basic and diluted share of $0.46.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the topline data from the URIROX-1 clinical trial and Study 206, Allena’s ongoing review of these data and implications for the future clinical, regulatory and commercial potential of reloxaliase, statements regarding the ability of reloxaliase to provide clinical benefit to patients, statements regarding future plans for the URIROX-2 clinical trial, including the adaptive design elements of this trial, statements regarding the future development of reloxaliase for patients with EH and advanced CKD, statements regarding the URIROX clinical program generally, statements regarding Allena’s ability to utilize the accelerated approval regulatory pathway for reloxaliase, and statements regarding Allena’s development of ALLN-346, including the expected timing of its IND filing. In addition, it should be noted that additional capital will be required to complete the planned URIROX-2 clinical trial, which capital may not be available to Allena on terms that are acceptable to it, if at all. If adequate funds are not available on a timely basis, Allena may be required to amend, delay, limit, reduce or terminate one or more of its ongoing or planned clinical trials of its product candidates. Any forward- looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that Allena’s clinical and regulatory strategy for reloxaliase may evolve following further review of the topline data from the URIROX-1 clinical trial and Study 206, including without limitation, modifications or termination of the planned URIROX-2 clinical trial; the risk that the results of the URIROX-1 clinical trial may not be replicated in the URIROX-2 or other clinical trials of reloxaliase; the risk that the reduction in 24-hour UOx excretion observed in the placebo arm of the URIROX-1 trial may be observed in the URIROX-2 or other clinical trials of reloxaliase, which may have a negative impact on Allena’s ability to secure regulatory approval for this product candidate; the risk that results of earlier studies, or interim results, may not be predictive of future clinical trial results, and planned and ongoing studies may not establish an adequate safety or efficacy profile for reloxaliase to support regulatory approval or the use of the accelerated approval regulatory pathway; risks related to Allena’s ability to utilize the accelerated approval pathway for reloxaliase, including the risk that available data at the time of any sample size re-estimation or interim analysis conducted during the URIROX-2 trial may not be sufficient to demonstrate an increased probability of kidney stone events in patients with enteric hyperoxaluria and increasing UOx levels; the risk that the FDA may require that Allena increase the sample size or duration of treatment following the sample size reassessments to be conducted in accordance with the adaptive design element of the trial or otherwise collect additional clinical data from the URIROX-2 or other clinical trials prior to submitting a BLA for reloxaliase; risks associated with Allena’s ability to enroll a sufficient number of patients to adequately power URIROX-2 in order to achieve ultimate statistical success for kidney stone disease progression in the long-term follow-up phase of the trial; risks related to Allena’s use of UOx and/or POx as surrogate endpoints in its ongoing clinical trials, neither of which it believes have been previously utilized as biomarkers to support regulatory approval of other drug candidates, and the risks related to validating that reductions in UOx and/or POx correlate with meaningful clinical benefit; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Allena’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risk associated with Allena’s financial condition and its need to obtain additional funding to support its business activities, including the future clinical development of reloxaliase; and risks associated with Allena’s dependence on third parties. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Allena’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Item 1A of Part II of Allena’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, as well as discussions of potential risks, uncertainties and other important factors in Allena’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.
|Allena Pharmaceuticals, Inc|
|Selected Condensed Consolidated Balance Sheet Data|
|As of September 30,
|As of December 31,
|Cash and cash equivalents||$||39,419||$||61,643|
|Working capital (1)||31,091||58,706|
|Loan payable, net of current portion and discount||6,986||9,980|
|Total stockholders' equity||25,191||49,456|
|(1) The Company defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial statements for further detail regarding its current assets and current liabilities.|
|Allena Pharmaceuticals, Inc|
|Condensed Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
|For the Three Months Ended
|For the Nine Months Ended
|Research and development||$||10,806||$||7,316||$||28,523||$||19,107|
|General and administrative||2,532||2,389||7,709||6,706|
|Total operating expenses||13,338||9,705||36,232||25,813|
|Other income (expense), net||50||195||252||(224||)|
|Net loss per share attributable to common
stockholders—basic and diluted
|Weighted-average common shares
outstanding—basic and diluted
Stern Investor Relations, Inc.
Berry & Company Public Relations
Source: Allena Pharmaceuticals, Inc.